Ace inhibition in renal disease: risks and benefits.
The kidney is one of the principal target organs of hypertension and most diseases of the kidney are associated with blood pressure elevation. Studies in animal models of hypertensive renal disease have provided insights into the complex relationship between systemic and glomerular hypertension. The intrarenal renin-angiotensin system (RAS) appears to play an important role in the pathogenesis of progressive glomerular injury. Thus, angiotensin converting enzyme inhibitors (ACEi) may have a specific therapeutic advantage in the treatment of hypertension associated with progressive renal disease. However, in contrast to their possible renoprotective effect in diabetic nephropathy or in renal hypertension, there are increasing evidence that, in the presence of a reduction in renal perfusion, intrarenal haemodynamic effect of ACEi may lead to compromised renal function. ACEi appear to have dual effects on renal function depending on the setting in which they are administered.
Campanacci
L
L
Istituto di Patologia Medica, University of Trieste, Italy.
Fabris
B
B
Fischetti
F
F
Bardelli
M
M
Vran
F
F
Carretta
R
R
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy; D006801:Humans; D006978:Hypertension, Renovascular / Q000188:drug therapy; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000188:drug therapy* / Q000503:physiopathology
D000806:Angiotensin-Converting Enzyme Inhibitors